Keep Me Logged In
Shares of Alkermes are up nicely after positive data from its schizophrenia drug trial. Richard Pops, Alkermes CEO, provides insight to the enormous market for schizophrenia and depression.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2018 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by